



Silere Medical Technology Licensing Agreement Press Release

February 8th, 2010

FOR IMMEDIATE RELEASE

Contact: Michael F. Langhout, CEO and President, Silere Medical Technology, Inc.

+1-425-269-3000

IP Secured for Neurostimulation Device for Suppression of Chronic Tinnitus
Silere MedTech Secures Exclusive Licensing Rights from University of Iowa
US Patents Authored By Jay T. Rubinstein, MD, PhD, Chief Medical Officer
Engineered Suppression of Tinnitus™

Kirkland, Washington, January 8th, 2009 - Medical device startup Silere Medical Technology, Inc. announced today that it has entered into an exclusive licensing agreement covering three United States issued patents with the University of Iowa Research Foundation. The three patents allow Silere Medical Broad IP protection on key technology that will be used to design, fabricate, and bring to market its TheraStim 6000™ electronic neurostimulation device.

“We have successfully demonstrated suppression of tinnitus in human patients, 71% of whom reported a beneficial suppression of the tinnitus percept within minutes of application of Silere’s proprietary therapeutic signal strategy. The therapy was successful in 10 of 14 patients studied”, said Jay T. Rubinstein, MD, PhD, and Chief Medical Officer.

“An effective neural prosthesis for even a small percentage of the population with tinnitus would have a profound impact on my clinical practice, and provide me with a much needed tool to treat this difficult and debilitating affliction”, said J. Thomas Roland Jr., MD., NYU Langone Medical Center, Director, Cochlear Implant Center, member of Silere Medical Advisory Board.

Michael Langhout, CEO and co-founder of Silere, said “With the initial proof of concept completed as described in these patents, a confirmatory study is now planned. This clinical study will primarily target device safety, but will also provide basic efficacy data. The Silere team has extensive experience in neurostimulation, and is confident it can produce an effective neural stimulation device that will be very exciting for neurologists globally, who currently are unable to offer an effective solution to this large unmet clinical need”.



Silere Medical is a medical device company developing an electrical neural prosthesis targeting suppression of chronic tinnitus. Regulatory strategy for the company includes clinical trials in European centers to obtain CE Mark, concurrent with feasibility and pivotal IDE studies in the United States.

This platform builds on the technology of neural pain suppression stimulators and the cochlear implant, the most sophisticated neural prosthetic currently in distribution. Much has been learned about this technology used in these devices over the past three decades which further reduces device and business risk. Additionally, there has been significant development and refinement in the surgical methods used to implant these devices and the clinical techniques needed to fit them to patients.

“With this device, Silere will apply and refine the technology developed for and used in cochlear implants during the past decade. We will integrate our proprietary electrode technology and system design technology into system to provide a robust and highly functional product that provides the clinician a powerful flexible platform to treat tinnitus. The TheraStim 6000™, the first microelectronic Implantable Therapeutic Stimulator (ITS) designed to suppress chronic tinnitus, will be the first in a series of products SILERE plans to develop to treat tinnitus and other conditions that respond to neural stimulation” said William ‘Van’ Harrison, co-founder, Executive Chairman and CTO.

About Silere Medical Technology

Based in Kirkland, WA, Silere Medical intends to design, fabricate, and market electrical neurostimulation devices treating disorders of the auditory processing system. The primary and initial focus is chronic tinnitus, a condition which can be debilitating for millions. Silere’s unique treatment method was developed at University of Iowa by Jay Rubinstein, MD, PhD, and internationally recognized thought leaders in disorders of the auditory processing system, cochlear implants, and tinnitus research.

Silere Medical was co-founded by industry veterans, including William ‘Van’ Harrison, Jay T. Rubinstein, MD., PhD, Michael Langhout, Dorcas Kessler, MA, and Chris Zobkiw. Silere Medical has been financed by its founders through to its demonstration of Proof of Concept in man, and is now in active discussions with Series “A” investors to support the larger confirmatory studies.”